Brought to you by 
Esperance raises $5.7mm through first closing of Series B round
08 Jul 2011
Executive Summary
Esperance Pharmaceuticals Inc. (anticancer peptide therapeutics) raised $5.7mm in the first closing of its Series B round, which is expected to generate a total of $7.5mm. Sanofi invested $4.5mm, and earmarked $1.5mm of that specifically for clinical and regulatory services related to continued development of Esperance's EP100, a Phase I solid tumor candidate. All of Esperance's existing backers also participated including Louisiana Fund I, Themelios Ventures (managed by BVM Capital), Research Corp. Technologies, Advantage Capital Partners/Louisiana Technology Fund, and five other investors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Esperance raises $5.7mm through first closing of Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice